APC-EPCR-PAR1通路在类风湿关节炎中的研究进展  

Research progress of APC-EPCR-PAR1 pathway in rheumatoid arthritis

作　　者：刘轩绮 刘汇洋 赵京洋 尹芳蕊[1,2,3] 白力 王永福[1,2,3] LIU Xuanqi;LIU Huiyang;ZHAO Jingyang;YIN Fangrui;BAI Li;WANG Yongfu(Department of Rheumatology and Immunology,the First Affiliated Hospital of Baotou Medical College(Institute of Rheumatology and Immunology,Baotou Medical College),Baotou 014000,China;Baotou Medical College,Inner Mongolia University of Science and Technology;Inner Mongolia Autoimmune Key Laboratory)

机构地区：[1]包头医学院第一附属医院风湿免疫科,包头医学院风湿免疫研究所,014000 [2]内蒙古科技大学包头医学院 [3]内蒙古自治区自体免疫学重点实验室

出　　处：《天津医药》2022年第5期552-556,共5页Tianjin Medical Journal

基　　金：内蒙古自治区自然科学基金资助项目(2020LH08001,2021BS08006)。

摘　　要：类风湿关节炎(RA)是一种慢性、系统性自身免疫性疾病。活化蛋白C(APC)是由其前体蛋白C(PC)转化而来的一种天然抗凝血剂,在凝血调控中起着关键的作用。APC可与内皮蛋白C受体(EPCR)结合,激活内皮细胞上的蛋白激酶受体1(PAR1),从而启动细胞的保护和抗炎反应。现就APC-EPCR-PAR1活化通路上各靶点在RA中的研究进展进行综述,探讨APC-EPCR-PAR1通路在RA疾病中的潜在治疗价值,为RA的治疗提供更多的选择。Rheumatoid arthritis(RA)is a chronic and systemic autoimmune disease.Activated protein C(APC)is a natural anticoagulant transformed from its precursor protein C(PC),which plays a key role in the regulation of blood coagulation.APC can bind to endothelial protein C receptor(EPCR)and activate protein kinase receptor 1(PAR1)on endothelial cells,thereby initiating cell protection and anti-inflammatory response.This article summarizes the research progress of each target on the APC-EPCR-PAR1 activation pathway in RA,discusses the potential therapeutic value of APC-EPCR-PAR1 pathway in RA diseases,and provides more options for the treatment of RA in the future.

关 键 词：关节炎 类风湿 蛋白质C 受体 细胞表面 蛋白酪氨酸激酶类 APC-EPCR-PAR1通路 

分 类 号：R392.12[医药卫生—免疫学]